Monday, November 29

Pfizer shares rise more than 8% after results of its pill against COVID-19

The shares of the US pharmaceutical company Pfizer have welcomed with increases of more than 8% the announcement of the company that its new candidate for oral antiviral in the investigation phase, ‘PAXLOVID‘, reduces by 89% the risk of hospitalization or death due to COVID-19.

In this way, the laboratory’s shares were trading above $ 48 on Friday for the first time since the end of last August.

According to a provisional analysis of the study of fase 2/3 ‘EPIC-HR’ Randomized and double-blind, the Pfizer drug showed an 89% reduction in the risk of hospitalization or death from any cause related to Covid-19 compared to placebo in patients treated within three days of symptom onset , the company said.

0.8% of patients who received ‘PAXLOVID‘were hospitalized until the 28th day after randomization (3/389 hospitalized with no deaths), compared with 7% of patients who received placebo and were hospitalized or died (27/385 hospitalized with seven subsequent deaths).

On the recommendation of an independent data oversight committee and in consultation with the US Food and Drug Administration (FDA), Pfizer will stop enrolling more patients in the study due to the “overwhelming efficacy” demonstrated in these results.

Therefore, he plans to submit the data for authorization in the US “as soon as possible.”

“Today’s news is a true game changer in global efforts to stem the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or licensed by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of ten hospitalizations. Given the continuing global impact of Covid-19, we have remained focused on science and fulfilling our responsibility to help health systems and institutions around the world, while ensuring equitable and comprehensive access for people across the world. all over the world ”, said the president and CEO of Pfizer, Albert Bourla.

If approved or authorized, ‘PAXLOVID‘would be the first oral antiviral of its kind, a protease inhibitor of the SARS-CoV-2-3CL specifically designed.

Upon successful completion of the remainder of the clinical development program and subject to approval or authorization, it could be prescribed more widely as home treatment to help reduce disease severity, hospitalizations, and deaths, as well as reduce the probability of infection after exposure, among adults.

Furthermore, the drug has demonstrated potent ‘in vitro’ antiviral activity against the circulating variants of interest, as well as against other known coronaviruses, suggesting its potential as a therapy for multiple types of coronavirus infections.

Leave a Reply

Your email address will not be published. Required fields are marked *